This study assessed the fortification of muffins with 2, 4, and 6 % of brewer's spent grain protein hydrolysates to enhance their in vitro antioxidant, α-glucosidase, and α-amylase inhibitory activities. In addition, oxidative stability, hardness, color and sensory properties of fortified muffins were investigated. The fortification of muffin formulations with 6 % hydrolysates increased antioxidant activity six times higher than that of the control sample. As the hydrolysate increased to 6 %, the α-amylase and α-glucosidase inhibition also increased to 88 and 40 %, respectively. The 6 % fortified muffins exhibited lower peroxide and thiobarbituric acid values during a 14 day storage than the control muffins, while higher hydrolysate levels darkened the color and softened the texture. Sensory evaluation indicated that muffins with 2% hydrolysates achieved similar overall acceptance as the control. It can be concluded that brewer's spent grain hydrolysate is suitable for functional bakery products.
The mechanism of enhanced effect of (-)-epigallocatechin-3-gallate (EGCG) on huperzine A's (HUP) inhibition of acetylcholinesterase (AChE) activity in rats was investigated. The inhibitory effects of HUP at 10 and 5 microg/kg on AChE activity were quite weak in the whole phase. In contrast, upon addition of EGCG (100 mg/kg) to the HUP 10 and 5 microg/kg groups, remarkably enhanced inhibitory effects with maximum inhibitory percentages of 90.94 and 88.13% were observed under the same conditions. EGCG also can greatly prolong the inhibitory time. The mechanism of the enhanced effects of EGCG on HUP's inhibition of AChE activity was investigated by steady fluorescence spectroscopy, infrared spectroscopy, and ultraviolet spectroscopy. HUP hardly interacted with the main transport protein, whereas there was a very strong binding interaction between EGCG and bovine serum albumin. The enhanced transport of HUP is a possible cause of the enhanced effect of EGCG on HUP bioactivity.
A number of observational studies have found that treated hypertensive patients, even those with controlled clinic blood pressure (BP), might have poorer prognosis than untreated hypertensives. Different trials have also shown that relatively low cardiovascular disease (CVD) risk cannot be achieved in high-risk hypertensive patients, leading to the belief they have a "residual CVD risk" that cannot be attenuated by conventional treatment. All these conclusions disregard the facts that the correlation between BP level and CVD risk is stronger for ambulatory than clinic BP and that the BP-lowering efficacy and effects on the 24-h BP pattern of different classes of hypertension medications exhibit statistically and clinically significant treatment-time (morning versus evening) differences. Accordingly, we evaluated the potential differential administration-time-dependent effects on CVD risk of the various classes of hypertension medications and the number of them used for therapy in the MAPEC (Monitorización Ambulatoria para Predicción de Eventos Cardiovasculares, i.e., Ambulatory Blood Pressure Monitoring for Prediction of Cardiovascular Events) study, a prospective, open-label, blinded-endpoint trial on 2156 hypertensive patients (1044 men/1112 women), 55.6 ± 13.6 (mean ± SD) yrs of age, randomized to ingest all prescribed once-a-day hypertension medications upon awakening or the entire daily dose of ≥1 of them at bedtime. Ambulatory BP was measured for 48 h at baseline, and again annually or more frequently (quarterly) when adjustment of treatment was necessary to achieve ambulatory, i.e., awake and asleep, BP control. CVD risk according to the number and classes of medications used at the final evaluation was calculated by comparison with that of 734 normotensive subjects who were identically followed and remained untreated. After a median follow-up of 5.6 yrs, CVD risk of hypertensive patients randomized to ingest all medications upon awakening was progressively higher with increase in the number of medications (adjusted hazard ratio [HR]: 1.75, 2.26, 3.02, and 4.18 in patients treated with 1, 2, 3, and ≥4 medications daily, respectively; p < .001 compared with normotensive subjects). CVD risk was markedly lower in patients ingesting ≥1 medications at bedtime (HR: .35, 1.45, .94, and 2.28 with 1, 2, 3, and ≥4 medications daily, respectively), and even lower in patients ingesting all medications at bedtime (HR: .35, .39, .87, and .79 with 1, 2, 3, and ≥4 medications daily, respectively). Patients ingesting ≥1 medications at bedtime evidenced significantly lower CVD risk than those ingesting all medications upon awakening, independent of class. Greater benefits were observed for bedtime compared with awakening treatment with angiotensin-II receptor blockers (ARBs) (HR: .29 [95% confidence interval, CI .17-.51]; p < .001) and calcium channel blockers (HR: .46 [95% CI: .31-.69]; p < .001). CVD risk was similar for all six classes of tested hypertension medications in patients randomized to ingest all of them upon awakening. Among patients randomized to ingest ≥1 medications at bedtime, however, ARBs were associated with significantly lower HR of CVD events than ingestion of any other class of medication also at bedtime (p < .017). We document significantly reduced CVD risk among hypertensive patients ingesting medications at bedtime, independent of the number of hypertension medications required to achieve proper ambulatory BP control. These findings challenge the current belief of "residual CVD risk," as a bedtime-treatment regimen of current hypertension medications, even in risk-high patients, can reduce such risk.
A nanoplatform accomplishes simultaneous laser-induced heat generation by gold nanoparticles and temperature sensing by (Gd,Yb,Er)2O3 nanorods, presenting considerable potential for hyperthermia and deep-tissue optical imaging. On page 4868, Luis D. Carlos, J. Rocha and co-workers assess the local temperature from the Boltzmann distribution of the Er3+ up-conversion 2H11/2→4|15/2/4S3/2→4|15/2 intensity ratio (300–1050 K) or Planck's law for white-light emission (1200–2000 K).
Evaluation of Testosterone-Sensitive Gene Alterations in Cyprinodon variegatus Larvae for Development of a Tool of Androgen Endocrine Disruptors 1Raquel Abad Pérez, 1Alexandre M. Schönemann, 1Ricardo Beiras 1Centro de Investigacion Mariña, University of Vigo (CIM-UVigo), Vigo, Galicia, Spain raquel021x@gmail.com The increase in plastic waste that appears in the seas has turned out to be an ecosystem problem. The additives contained in plastics have a very high toxic potential that makes it necessary to analyse substances that are potentially toxic and harmful to ecosystems. One of the consequences of some endocrine disruptors (ED), is the disruption of the hormonal system that causes an adverse effect on an organism, its progeny, or its population, having been classified as substances of "very high concern" and legislated by the European Union according to the "REACH Regulation". In addition, it is known that the presence of endocrine disrupting compounds can have a permanent impact on organisms, especially if they are in the development phase. In order to be able to study these substances with endocrine disruptive potential and their effects on marine vertebrates we have added biomarkers of androgenicity to the molecular tool “CyVa test”, that was specialized only on estrogenicity up to date. An experiment was carried out to verify the reliability of selected androgenic biomarkers, thus being able to verify the molecular responses presented by the marine fish Cyprinodon variegatus to acute exposure to androgenic compounds. C. variegatus larvae were exposed to testosterone in three different concentrations (10, 100 and 1000 ng/L). Quantitative PCR (qPCR) was used to observe changes on expression of 11 β Hydroxysteroid dehydrogenase (11HSD) and 17 β Hydroxysteroid dehydrogenase (17HSD) when exposed to testosterone and have been integrated to “CyVa test” tool. Thus, demonstrating the efficacy of the selected biomarkers for future detection of androgenic endocrine disruptors.